On Tuesday, August 11, Samsung Biologics announced it will invest $2 billion to build a new pharmaceutical “super plant” in Incheon, South Korea. According to the press release, the new facility is part of Samsung’s long term strategy to maximize its operational efficiency and scale up its development and manufacturing…